Search

Displaying results 691 - 700 of 2817 in total
  1. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion.

  2. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

  3. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    [L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

  4. Indication

    Abdominal Pain

    go.drugbank.com/conditions/DBCOND0029201
    Drugs: Aluminum hydroxide · Alverine · Anise oil · Bacillus clausii · Ethyl piperidinoacetylaminobenzoate · Itopride +2 more
    Synonyms: Gut pain
  5. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    Approved

    Docusate acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass [L1801]. Docusate can be orally or rectally administered.

  6. Drug

    Avobenzone

    go.drugbank.com/drugs/DB09495
    ApprovedInvestigational

    Avobenzone is dibenzoyl methane derivative. It is oil soluble ingredient. Avobenzone has the ability to absorb ultraviolet light over wider range of wavelengths. It is included in many commercially available sunscreens which are used as ...

    Mixtures: Select Brand Sunscreen, Select Brand SunscreenCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Indication

    Mucopolysaccharidosis Type VII

    go.drugbank.com/conditions/DBCOND0063470
    Drugs: Vestronidase alfa
    Synonyms: GUS deficiency
  8. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [L880,L42500,L42510] It is marketed under the brand name Diacomit.

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  9. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

  10. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary